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mias. Health-care utilization and cost data for each of the
two patient categories were averaged and annualized.
Costs were converted from local currencies to Euros.
RESULTS: The mean annual health-care costs in patients
with bradycardia alone was 7,787 EUR (95%CI 6,176 to
10,040 EUR) in the US, 3,860 EUR in Germany, and
3,765 EUR in the UK compared to 22,043 EUR (95%CI:
15,060 to 30,759 EUR) in the US, 14,720 EUR in Ger-
many, and 10,407 EUR in the UK for patients with
bradycardia and atrial tachycardias. Atrial tachycardia
results in an additional two- to three-fold increase in
costs per year. The main cost driver in the US and Ger-
many was hospitalizations whereas the main cost driver
in the UK was the cost of procedures.
CONCLUSION: Atrial tachyarrhythmias impose a large
incremental burden on health-care utilization and costs in
bradycardia patients.
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OBJECTIVE: The purpose of this study was to examine
the effect of amlodipine treatment on cardiovascular dis-
ease (CVD) related hospital admissions and the corre-
sponding costs in patients with coronary artery disease
(CAD) in Spain.
METHODS: This analysis used data from Prospective
Randomized Evaluation of the Vascular Effects of Nor-
vasc Trial (PREVENT), a double-blind, randomized, pla-
cebo-controlled, multi-center clinical trial. A decision-
tree model was used to analyze the expected incremental
cost of amlodipine treatment relative to placebo. A sensi-
tivity analysis was conducted to examine the robustness
of the study outcome. The hospital costs were estimated
using the DRG’s from the Medicare adjusted to the me-
dian of a local hospital stay cost (Catalonian area).
RESULTS: Amlodipine significantly reduced the number
of CVD-related hospital admissions and procedures in pa-
tients with CAD relative to placebo. The expected CVD-
related hospital cost per patient in the placebo group ex-
ceeded costs for patients in the amlodipine group. The ex-
pected savings of CVD-related hospitalizations ranged
from 0 to 331 Euros per patient over the trial period in
1997 Spanish pesetas when the cost to charge ratio was
changed from 0.66 to 1.2. The total expected costs for the
amlodipine group were 1,723.5 Euros (533 for no CVD
hospitalization and 1190 for CVD hospitalization) while
the total expected costs for the placebo group were 1929
Euros (119 for No CVD hospitalization and 1810 for
CVD hospitalization). At the breakeven point (the cost to
charge ratio  0.66), the amlodipine treatment still offset
the drug cost of amlodipine.
CONCLUSIONS: Use of amlodipine can reduce CVD-
related hospital admissions and associated costs in pa-
tients with coronary artery disease. Amlodipine is a cost-
saving agent in the treatment of patients with coronary
artery disease.
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OBJECTIVES: To install a world-wide-web (WWW, inter-
net) -based registry for the observation of treatment patterns
for unstable Angina Pectoris (uAP) and to estimate the eco-
nomic burden of uAP in Germany from the perspective of
the statutory health insurance (Gesetzliche Krankenver-
sicherung) and of hospitals as service providers.
METHODS: Prospective, bottom-up, cross-sectional cost-
of-illness (COI) study. Three hundred sixteen patients con-
secutively included between November 2000 and May
2001 were documented via an Internet-based registry us-
ing standardized documentation forms. Inclusion and ex-
clusion criteria were pre-defined. Fifteen centers of differ-
ent healthcare levels (10 university hospitals, 1 specialized
hospital, 4 general hospitals) participated. Direct costs (for
diagnostic, medical treatment, surgery, drug therapy) and
indirect costs (due to lost productivity) associated with in-
patient treatment due to uAP were considered.
RESULTS: Mean age of patients was around 65 years for
females (34%) and 69 years for males (66%). In about
99% of cases, uAP was diagnosed at hospital admission:
47% were hospitalized as emergency cases; 26% were re-
ferred from other hospitals; 26% from office-based phy-
sicians. Mean hospital stay lasts 8.3 days per patient, 6.8
days of them spent in intensive care. Angiography or an-
gioplasty were performed on 78% of patients. About 4%
of patients underwent heart surgery, most of them for tri-
ple coronary bypass. 30% of patients received one of the
new platelet aggregation inhibitors (Abciximab, Eptifi-
batide, Tirofiban) during hospitalization.
CONCLUSIONS: Because the registry is still ongoing, cost
data are under evaluation, but will be finalized for poster
presentation. Treatment with platelet aggregation inhibi-
tors is still not very common, despite being recommended
by German therapy guidelines for uAP treatment.
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OBJECTIVE: With a prevalence up to 40% in the adult
population, chronic venous insufficiency (CVI) is one of
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the most common diseases in Poland. Only 13% of those
affected currently receive any kind of treatment. This is
the first study in Poland with the intention of demon-
strating the cost of CVI.
METHODS: A representative group of 1000 people over
18 years old was randomised, and 223 treated patients
were questioned by an external agency *. All the data
were collected with the help of a special resource utilisa-
tion questionnaire. Items measured included oral drugs,
topical drugs, compression therapy, surgical and cos-
metic interventions (sclerotherapy, operational proce-
dures), diagnostic tests (including Doppler investigation)
and hospitalizations. The value of social and family help,
sick leave and early retirement due to CVI were also esti-
mated (capital cost method).
RESULTS: The average total cost per person per year
from the study group was 952,94 PLN (1 EURO 
3,4517 PLN) with average direct costs of 233,39 PLN
and average indirect costs of 719,54. The total burden of
CVI in Poland in terms of direct medical costs may reach
6.5 billion PLN (24% of the total cost). The distribution
of total costs per person in the investigated group is as
follows: oral treatment, 37,93 PLN (4%); local treatment
(ointments, gels, creams), 26,15 PLN (3%); compression
therapy 11,52 PLN (1%); all surgical interventions 46,84
PLN (5%); hospitalisations (all wards) 110,95 PLN
(12%); family and social help 466,50 PLN (49%); sick
leave 108,15 PLN (11%); pensions 144,90 (15%).
CONCLUSION: CVI represents an important economic
burden for the Polish population. Among direct medical
costs, oral treatment and compression constitute only
21%, while the cost of hospitalisation accounts for 48%.
An early diagnosis, proper treatment and management of
CVI leading to an optimal allocation of expenditures may
contribute to a significant reduction of the total costs of
CVI in Poland.
* PENTOR - Medical - Institute for Opinion and Market
Research.
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OBJECTIVE: To investigate and quantify the impact on
total treatment costs of cardiovascular disease associated
with the use of amlodipine in patients with coronary ar-
tery disease (CAD) in the United Kingdom.
METHODS: A Markov cohort simulation model was de-
veloped to estimate the expected health outcomes and
costs of CAD cohorts on amlodipine versus placebo over
three years. Clinical outcomes included in the analysis
were: hospitalization for angina; hospitalization for MI;
hospitalization for congestive heart failure (CHF); PTCA;
CABG; various combinations of these events and proce-
dure-related outcomes, and death. Transitional probabili-
ties used in the model were based on patient-level data
from the Prospective Evaluation of the Vascular Effects
of Norvasc Trial (PREVENT). Health outcomes were dis-
counted at a rate of 1.5% and all costs were discounted
at a rate of 6%.
RESULTS: The amlodipine cohort experienced fewer
hospitalizations due to angina, CABG, PTCA, CHF, and
MI than the placebo cohort did. The rate of hospitaliza-
tion per patient in the placebo cohort was 61.8% while
that in the amlodipine cohort was 44.3%. The cost per
patient for treatment of CVD was £1,859 for amlodipine
patients and £1,800 for placebo patients over three years
of follow-up. For amlodipine use this equates to an incre-
mental cost per hospitalization avoided of £332.
CONCLUSION: In the UK, the use of amlodipine re-
sulted in improved clinical outcomes through a marginal
investment in cost.
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OBJECTIVE: To generate estimates of the cost-effective-
ness of thromboprophylaxis with enoxaparin versus no
thromboprophylaxis (usual care) in patients with acute
medical illness in the health-care setting of Italy from the
NHS perspective.
METHODS: Markov process analysis techniques were
used to model the health-economic outcomes. Data col-
lection was based on probabilities of clinical events from
clinical trial data from the MEDENOX trial and other
published literature, OECD country-specific general pop-
ulation mortality and Delphi panels. Units of health-care
utilization were derived from the Delphi panels. Prices
and tariffs were derived from official lists.
RESULTS: Analysis over one year showed that the cost
per venous thromboembolic (VTE) event avoided was
Lit4.500.586 (EURO 2324) and cost per life saved was
Lit16.042.624 (EURO8285), when assuming no higher
risk for morbidity and mortality for asymptomatic pa-
tients. The lifetime model (again, assuming no higher risk
for recurrence of VTE in asymptomatic patients), showed
that enoxaparin increased the total costs from Lit804.900
(EURO416) to Lit1.180.000 (EURO609), while the life ex-
pectancy increased from 14.11 to 14.43 years. Consequently,
cost per life year gained was Lit1.172.188 (EURO605),
and the cost per event avoided was Lit4.343.446
(EURO2.243).
CONCLUSION: The results showed that the favorable
clinical benefit of enoxaparin observed in MEDENOX
